Research Papers:
TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3450 views | HTML 3549 views | ?
Abstract
Xing Liu1,2, Weijia Liao4, Qing Yuan1, Ying Ou1, Jian Huang1,2,3
1National Engineering Center for Biochip at Shanghai, Shanghai, China
2Shanghai-MOST Key Laboratory for Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China
3Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China
4Hepatology Institute of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
Correspondence to:
Jian Huang, e-mail: [email protected]
Xing Liu, e-mail: [email protected]
Keywords: hepatocarcinogenesis, TTK gene, cell migration, demethylation, Akt
Received: April 19, 2015 Accepted: September 07, 2015 Published: September 19, 2015
ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most malignant cancers with poor clinical outcome. The protein kinase human monopolar spindle 1 (hMps1/TTK) gene expression is significantly increased in HCCs. However, its contributions to hepatocarcinogenesis remain unclear. In this study, we found that TTK was overexpressed in 77.63% (118/152) HCC specimens. Elevated TTK expression positively correlated with large tumor size and presence of the portal vein tumor thrombus (PVTT). Demethylation in its promoter increased TTK expression in HCC. In vitro assays revealed that TTK not only promoted cell proliferation and anchorage-independent growth, but also cell migration. Subsequent investigations revealed that TTK activated Akt/mTOR pathway in a p53 dependent manner. We also found that TTK specific kinase inhibitor AZ3146 could decrease HCC cell growth. In conclusion, TTK contributes to HCC tumorigenesis via promoting cell proliferation and migration. It may serve as a novel biomarker and a potential target in HCC cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5295